Nicotinamide Riboside slows Amyotrophic Lateral Sclerosis (ALS) in human trial

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig’s disease, is a specific disease which causes the death of neurons controlling voluntary muscles. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. Half of people develop at least mild difficulties with thinking and behavior and most people experience pain. Most eventually lose the ability to walk, use their hands, speak, swallow, and breathe. No cure for ALS is known. The average survival from onset to death is two to four years.

Researchers in Spain setup a human pilot study were particpants were randomized to receive Nicotinamide Riboside (NR) or placebo and underwent evaluation for 4 months. The participants also received Pterostilbene. After 4 months in the patients receiving NR the progression of ALS was slowed significantly.

Previous research such as Enhancing NAD+salvage pathway reverts the toxicity of primary astrocytes expressing amyotrophic lateral sclerosis-linked mutant SOD1 also made the link to NAD+ availability and hence is suggestive that boosting NAD+ may be an effective method to combat ALS.

In more detail  participants had significant improvements in pulmonary function, muscular strength, and in the skeletal muscle/fat weight ratio. The dosing was in the range of  2 doses of 500-600mg of Nicotinamide Riboside / day.

Nicotinamide riboside is available in a stable and safe formulation (Niagen) on the market and for sale, for example on Amazon or the TruNiagen website and based on these study results it appears that patients may well benefit from trying out this relatively cheap supplement.

You can find the study here.


Leave a Reply